{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:04:04Z","timestamp":1792803844399,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lansea.2024.100422","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:54:53Z","timestamp":1715597693000},"page":"100422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-8759","authenticated-orcid":false,"given":"Anurag","family":"Bhargava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lansea.2024.100422_bib1","series-title":"WHO consolidated guidelines on tuberculosis. Module 1: prevention- tuberculosis preventive treatment","year":"2020"},{"issue":"23","key":"10.1016\/j.lansea.2024.100422_bib2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.lansea.2024.100422_bib3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lansea.2024.100422_bib5","series-title":"National TB elimination programme. Central TB division","year":"2021"},{"key":"10.1016\/j.lansea.2024.100422_bib6","series-title":"Tuberculosis preventive treatment: rapid communication","year":"2024"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.lansea.2024.100422_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.lansea.2024.100422_bib9","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/cid\/ciad083","article-title":"Symptoms and systemic drug reactions in persons receiving weekly rifapentine plus isoniazid (3HP) treatment for latent tuberculosis infection","volume":"76","author":"Sadowski","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A\u00a0systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.lansea.2024.100422_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.lansea.2024.100422_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/tmi.13940","article-title":"Implementation of tuberculosis preventive therapy with INH-Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: a prospective study","volume":"28","author":"Sharma","year":"2023","journal-title":"Trop Med Int Health"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib13","article-title":"Uptake and completion of tuberculosis preventive treatment using 12-dose, weekly isoniazid-rifapentine regimen in Bangladesh: a community-based implementation study","volume":"9","author":"Rahman","year":"2023","journal-title":"Trop Med Infect Dis"},{"issue":"8","key":"10.1016\/j.lansea.2024.100422_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.5588\/ijtld.21.0676","article-title":"Implementing 3HP vs. IPT as TB preventive treatment in Pakistan","volume":"26","author":"Jaswal","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"issue":"4","key":"10.1016\/j.lansea.2024.100422_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/cid\/ciad245","article-title":"Scale-up of rifapentine and isoniazid for tuberculosis prevention among household contacts in 2 urban centers: an effectiveness assessment","volume":"77","author":"Hussain","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2024.100422_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2019.10.005","article-title":"Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers","volume":"158","author":"Jo","year":"2019","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.lansea.2024.100422_bib17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/cid\/ciac573","article-title":"How flu-like syndromes contribute to termination of weekly rifapentine-based TB preventive therapy is still poorly predictable","volume":"75","author":"Chang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2024.100422_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.lansea.2024.100422_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cmi.2020.06.008","article-title":"Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial","volume":"27","author":"Ruan","year":"2021","journal-title":"Clin Microbiol Infection"},{"issue":"6","key":"10.1016\/j.lansea.2024.100422_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01470-2018","article-title":"Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study","volume":"52","author":"Gao","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lansea.2024.100422_bib22","series-title":"Common terminology criteria for adverse events (CTCAE) version 5","year":"2017"},{"issue":"5","key":"10.1016\/j.lansea.2024.100422_bib23","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1093\/cid\/ciaa1741","article-title":"Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.lansea.2024.100422_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A\u00a0systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9237","key":"10.1016\/j.lansea.2024.100422_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lansea.2024.100422_bib26","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.lansea.2024.100422_bib27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bcp.15527","article-title":"Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: a population pharmacokinetic analysis","volume":"89","author":"Lee","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0041-3879(74)90069-5","article-title":"Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects","volume":"55","author":"Eule","year":"1974","journal-title":"Tubercle"},{"issue":"3","key":"10.1016\/j.lansea.2024.100422_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1164\/arrd.1983.128.3.419","article-title":"Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis","volume":"128","author":"Dutt","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.lansea.2024.100422_bib31","first-page":"598","article-title":"Isoniazid, Para-aminosalicylic acid and Streptomycin intolerance in 1744 patients. An analysis of reactions to single drugs and drug groups plus data on multiple reactions, type and time of reactions and desensititation","volume":"90","author":"Berte","year":"1964","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.lansea.2024.100422_bib32","first-page":"812","article-title":"Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI","volume":"8","author":"Lee","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0041-3879(89)90066-4","article-title":"Severe \u2018flu\u2019-like symptoms due to isoniazid\u2014a report of three cases","volume":"70","author":"Motion","year":"1989","journal-title":"Tubercle"},{"issue":"5","key":"10.1016\/j.lansea.2024.100422_bib34","first-page":"545","article-title":"Isoniazid-induced anaphylaxis","volume":"43","author":"Crook","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.lansea.2024.100422_bib35","series-title":"WHO operational handbook on tuberculosis Module 4: treatment- drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.lansea.2024.100422_bib36","series-title":"Technical and operational guidelines for tuberculosis control in India","year":"2016"},{"key":"10.1016\/j.lansea.2024.100422_bib37","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","year":"2014"},{"key":"10.1016\/j.lansea.2024.100422_bib38","series-title":"The pharmacological basis of therapeutics","article-title":"Chemotherapy of tuberculosis and nontuberculous mycobacteria, including leprosy","author":"Ignatius","year":"2023"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1378\/chest.62.1.71","article-title":"Isoniazid: a review with emphasis on adverse effects","volume":"62","author":"Goldman","year":"1972","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.lansea.2024.100422_bib40","doi-asserted-by":"crossref","first-page":"ofaa144","DOI":"10.1093\/ofid\/ofaa144","article-title":"Seizures in an immunocompetent adult from treatment of latent tuberculosis infection: is isoniazid to blame?","volume":"7","author":"Navalkele","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.lansea.2024.100422_bib41","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1007\/s12325-023-02670-3","article-title":"Factors contributing to the change in overweight\/obesity prevalence among Indian adults: a multivariate decomposition analysis of data from the national family health surveys","volume":"40","author":"Verma","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.lansea.2024.100422_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(23)01231-X","article-title":"Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial","volume":"402","author":"Bhargava","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lansea.2024.100422_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-3879(86)90003-6","article-title":"Hepatic toxicity in south Indian patients during treatment of tuberculosis with short course regimens containing isoniazid, rifampicin and pyrazinamide","volume":"67","author":"Parthasarthy","year":"1986","journal-title":"Tubercle"},{"key":"10.1016\/j.lansea.2024.100422_bib44","series-title":"Technical guidelines for tuberculosis control in: central TB division","year":"2000"},{"key":"10.1016\/j.lansea.2024.100422_bib45","series-title":"Treatment of tuberculosis: guidelines for national programmes","year":"1997"},{"issue":"4","key":"10.1016\/j.lansea.2024.100422_bib46","first-page":"187","article-title":"The Revised National Tuberculosis Control Programme in India: time for revision of treatment regimens and rapid upscaling of DOTS-plus initiative","volume":"21","author":"Bhargava","year":"2008","journal-title":"Natl Med J India"},{"issue":"6","key":"10.1016\/j.lansea.2024.100422_bib47","first-page":"292","article-title":"Utilization of and barriers to public sector tuberculosis services in India","volume":"17","author":"Dandona","year":"2004","journal-title":"Natl Med J India"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03256314","article-title":"Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients","volume":"13","author":"Singh","year":"2009","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/ijmr.IJMR_2013_15","article-title":"N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis","volume":"145","author":"Hemanth Kumar","year":"2017","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.24911\/SJP.106-1584524803","article-title":"Pyridoxine in isoniazid-induced psychosis","volume":"22","author":"Yadav","year":"2022","journal-title":"Sudan J Paediatr"},{"issue":"8","key":"10.1016\/j.lansea.2024.100422_bib51","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/archinte.1990.00040031751029","article-title":"Reversal of prolonged isoniazid-induced coma by pyridoxine","volume":"150","author":"Brent","year":"1990","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.lansea.2024.100422_bib52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","article-title":"Nervous system effects of antituberculosis therapy","volume":"24","author":"Kass","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00063110-200504000-00007","article-title":"Pyridoxine in clinical toxicology: a review","volume":"12","author":"Lheureux","year":"2005","journal-title":"Eur J Emerg Med"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib54","article-title":"Risk of serotonin syndrome with isoniazid","volume":"65","author":"O'Brien","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.lansea.2024.100422_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5588\/pha.18.0017","article-title":"Pyridoxine for patients suffering from drug-susceptible tuberculosis in India","volume":"8","author":"Bhargava","year":"2018","journal-title":"Public Health Action"},{"key":"10.1016\/j.lansea.2024.100422_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nut.2019.01.017","article-title":"Prevalence of vitamin deficiencies in an apparently healthy urban adult population: assessed by subclinical status and dietary intakes","volume":"63-64","author":"Sivaprasad","year":"2019","journal-title":"Nutrition"},{"issue":"1","key":"10.1016\/j.lansea.2024.100422_bib57","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12879-023-08571-8","article-title":"Can vitamin B6 alleviate the adverse reactions of quadruple anti-Helicobacter pylori regimen?: randomized controlled trial","volume":"23","author":"Cui","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lansea.2024.100422_bib58","series-title":"WHO operational handbook on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment","year":"2022"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368224000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368224000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:12:27Z","timestamp":1734505947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368224000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":57,"alternative-id":["S2772368224000726"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2024.100422","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2024.100422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100422"}}